Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Severity of oral/mucosal burning pain/sensation · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 12 to 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.23 [2.36, 7.59]
Studies not reported
Moderate
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.76 [2.84, 7.99]
Studies not reported
Moderate
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal dexamethasone implant 0.7 mg changes surgery for glaucoma ‐ 24 months compared with intravitreal antiVEGF (very low certainty).
1 finding from 1 review
RR 3.02 [0.12, 73.56]
Studies not reported
Very low
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
1 finding from 1 review
Change in retinal thickness (micron) (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 36 months compared with sham (moderate certainty).
1 finding from 1 review
Use of IOP‐lowering medications · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 36 months compared with sham (moderate certainty).
1 finding from 1 review
Surgery for glaucoma · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg showed no clear difference in surgery for glaucoma ‐ 36 months compared with sham (low certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg may leads to lower gain of three or more lines visual acuity ‐ 12 months compared with intravitreal antiVEGF (low certainty).
1 finding from 1 review
RR 0.99
Studies not reported
Low
Change in retinal thickness (micron) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Seizure frequency · people with ADHD and epilepsy
1 finding from 1 review
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).
1 finding from 1 review
Seizure severity · people with ADHD and epilepsy
1 finding from 1 review
50% or greater reduction in seizure frequency · people with ADHD and epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ADHD symptoms · people with ADHD and epilepsy
1 finding from 1 review